Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity. A study published in the open-access journal in PLOS Biology by Tianyu Jiang at Shandong University, Qingdao, China and colleagues suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice.

A new study, published in Nature, outlines a method combining smartwatches and routine blood tests to better detect insulin resistance in its early stages, and its early validation testing has shown good accuracy.

An innovative platform developed by PKU researchers called “cf-EpiTracing” has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, or roughly a drop of blood. The research, published in Nature on March 4, 2026, was led by Professor He Aibin from the College of Future Technology and Professor Jing Hongmei from the Department of Hematology, PKU Third Hospital.

A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to researchers at UNIST. Led by Professor Joo Hun Kang in the Department of Biomedical Engineering at UNIST, the team has introduced a novel diagnostic chip that analyzes the adhesion properties of leukocytes, or white blood cells, to detect cancer recurrence and evaluate the effectiveness of chemotherapy.

“The smart mask is a low-cost way of providing continuous health care monitoring.”